In current clinical practice, despite ITH, patients with STAD are treated according to pathological staging and expression of certain cancer markers such as Hrb-b2 receptor tyrosine kinase 2 (HER2; Bang et al., 2010). This evidence concerns the gene ERBB2 and cancer.